Home  »  Business   »  Is Can-Fite BioPharma Ltd. (CANF) a Keeper?...

Is Can-Fite BioPharma Ltd. (CANF) a Keeper?

Can-Fite BioPharma Ltd. (AMEX:CANF) went down by -6.32% from its latest closing price compared to the recent 1-year high of $12.90. The company’s stock price has collected -15.36% of loss in the last five trading sessions.

Is It Worth Investing in Can-Fite BioPharma Ltd. (AMEX :CANF) Right Now?

Opinions of the stock are interesting as 1 analysts out of 2 who provided ratings for Can-Fite BioPharma Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $81.32, which is $61.51 above the current price. CANF currently public float of 3.14M and currently shorts hold a 1.54% ratio of that float. Today, the average trading volume of CANF was 20.58K shares.

CANF’s Market Performance

CANF stocks went down by -15.36% for the week, with a monthly drop of -30.29% and a quarterly performance of -36.54%, while its annual performance rate touched -60.83%. The volatility ratio for the week stands at 13.23% while the volatility levels for the past 30 days are set at 11.64% for Can-Fite BioPharma Ltd. The simple moving average for the period of the last 20 days is -18.54% for CANF stocks with a simple moving average of -43.58% for the last 200 days.

Analysts’ Opinion of CANF

Many brokerage firms have already submitted their reports for CANF stocks, with Maxim Group repeating the rating for CANF by listing it as a “Buy.” The predicted price for CANF in the upcoming period, according to Maxim Group is $7 based on the research report published on August 11th of the previous year 2017.

Rodman & Renshaw gave a rating of “Buy” to CANF, setting the target price at $6 in the report published on August 29th of the previous year.

CANF Trading at -32.81% from the 50-Day Moving Average

After a stumble in the market that brought CANF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.26% of loss for the given period.

Volatility was left at 11.64%, however, over the last 30 days, the volatility rate increased by 13.23%, as shares sank -28.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.01% lower at present.

During the last 5 trading sessions, CANF fell by -15.36%, which changed the moving average for the period of 200-days by -59.14% in comparison to the 20-day moving average, which settled at $5.73. In addition, Can-Fite BioPharma Ltd. saw -22.68% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for CANF

Current profitability levels for the company are sitting at:

  • -1505.51 for the present operating margin

The net margin for Can-Fite BioPharma Ltd. stands at -1478.90. The total capital return value is set at -127.90, while invested capital returns managed to touch -126.23.

Based on Can-Fite BioPharma Ltd. (CANF), the company’s capital structure generated 0.86 points at debt to equity in total, while total debt to capital is 0.85. Total debt to assets is 0.61, with long-term debt to equity ratio resting at 0.49. Finally, the long-term debt to capital ratio is 0.49.

When we switch over and look at the enterprise to sales, we see a ratio of -1.38, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 26.60 and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.35.